[Double-blind controlled trial on treatment of psychosomatic syndromes by a new tranquilizer combination].
D000293:Adolescent; D000328:Adult; D000342:Affective Symptoms / Q000150:complications / Q000188:drug therapy; D001285:Atropine / Q000008:administration & dosage / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D004341:Drug Evaluation; D004357:Drug Synergism; D005260:Female; D005767:Gastrointestinal Diseases / Q000188:drug therapy / Q000209:etiology; D006261:Headache / Q000188:drug therapy / Q000209:etiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy / Q000209:etiology; D010546:Perphenazine / Q000008:administration & dosage / Q000627:therapeutic use*; D011602:Psychophysiologic Disorders / Q000188:drug therapy*; D012893:Sleep Wake Disorders / Q000188:drug therapy / Q000209:etiology; D014149:Tranquilizing Agents / Q000008:administration & dosage / Q000627:therapeutic use*
D004338:Drug Combinations; D014149:Tranquilizing Agents; D001285:Atropine; D010546:Perphenazine
Ricerca controllata doppio-cieca sul trattamento delle sindromi psicosomatiche con una nuova combinazione tranquillante.